# US Delirium Market > US Delirium Market Research Report By Drug (First-generation Antipsychotics, Second-generation Antipsychotics, Benzodiazepines), By Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies), By Type (Hyperactive, Hypoactive, Mixed), By Diagnosis (Laboratory Tests, Physical Examination, Imaging test, Blood test, Urine test) and By End-User (Hospitals, Research Centers, Specialty Centers) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 5.3% - **2024:** $ 70.98 Million - **2025:** $ 74.74 Million - **2035:** $ 125.3 Million - **Key Players:** Johnson & Johnson (US), Roche Holding AG (CH), Pfizer Inc. (US), Bristol-Myers Squibb Company (US), Eli Lilly and Company (US), Novartis AG (CH), AstraZeneca PLC (GB), Merck & Co., Inc. (US), Sanofi S.A. (FR) **Report ID:** MRFR/Pharma/18369-HCR · **Pages:** 100 · **Author:** Vikita Thakur & Garvit Vyas · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-delirium-market-19916 --- ## Market Summary ## **US Delirium Market Overview** As per MRFR analysis, the US Delirium Market Size was estimated at 67.2 (USD Million) in 2023. The US Delirium Market Industry is expected to grow from 75 (USD Million) in 2024 to 135 (USD Million) by 2035. The US Delirium Market CAGR (growth rate) is expected to be around 5.489% during the forecast period (2025 - 2035). ### **Key US Delirium Market Trends Highlighted** The US Delirium Market is showing significant trends driven by an aging population, which is increasingly susceptible to delirium. As the number of older adults rises, there is growing awareness among healthcare professionals about the importance of early recognition and management of delirium. This rising concern is also leading to the development of educational programs and guidelines aimed at improving the quality of care for patients at risk. Furthermore, advancements in technology, such as telehealth and wearable devices, are allowing healthcare providers to monitor patients more effectively and ensure timely intervention, enhancing overall patient outcomes. ### **Opportunities within the US Delirium Market** Opportunities within the US Delirium Market include the expansion of integrative care approaches, which combine medical treatment with psychological and social support to manage the symptoms of delirium more holistically. Community initiatives focused on caregiver education and support are also on the rise, providing resources to families dealing with delirium, thereby fostering a supported environment for patients. The increasing collaboration between hospitals and community organizations creates a pathway for better patient management and intervention strategies. Recent trends indicate that there is a greater emphasis on research and evidence-based practices focused on delirium prevention and management. Initiatives funded by government health agencies reflect a commitment to enhancing understanding of delirium's underlying causes and risk factors. This trend towards prioritizing preventive measures is likely to contribute to better health outcomes for patients in the US. Overall, these developments suggest a positive shift in how delirium is handled within healthcare systems across the country. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **US Delirium Market Drivers** ### **Aging Population Contributing to Increased Delirium Cases** The aging population in the United States is a significant driver for the US [Delirium Market](../../../reports/delirium-market-5850) Industry. As per the U.S. Census Bureau, the number of individuals aged 65 and older is projected to reach approximately 95 million by 2060, nearly double from the 52 million reported in 2018. This demographic shift will likely lead to an increase in age-related health issues, including delirium. The American Geriatrics Society highlights that over 7 million older adults in the U.S. experience delirium annually, which is often associated with hospital stays and post-surgical complications. With the rise in hospitalizations among the elderly due to surgical procedures and acute illnesses, the demand for delirium management products and services will continue to grow, effectively pushing the market forward. ### **Increased Awareness and Diagnosis of Delirium** Raising awareness about delirium among healthcare professionals and the general public is significantly improving diagnosis rates. The National Institute on Aging reports that education programs and clinical guidelines about delirium have increased recognition and understanding among healthcare providers. With the standardization of practices and increased screening tools being implemented in hospitals, more cases of delirium are being identified. This heightened awareness leads to improved care quality and creates a corresponding demand for treatment options within the US Delirium Market Industry, ultimately driving market growth. ### **Technological Advancements in Delirium Assessment Tools** Technological innovations in medical devices and assessment tools are revolutionizing the US Delirium Market Industry. The integration of artificial intelligence and machine learning algorithms in delirium detection methods is enhancing the speed and accuracy of diagnosis. For example, new software solutions can swiftly analyze patient data to identify delirium risk factors. The U.S. Food and Drug Administration has been actively promoting digital health technologies, which encourages innovation in this sector. As technology continues to advance and provide more reliable assessment tools, the market for delirium products will expand, positively influencing its growth trajectory. ## **US Delirium Market Segment Insights** ### **Delirium Market Drug Insights** The Drug segment within the US Delirium Market is crucial as it addresses the increasing prevalence of delirium, commonly affecting hospitalized patients and the elderly population. As the US population ages, the demand for effective treatment options is becoming more significant. First-generation antipsychotics have historically been used for managing delirium symptoms due to their ability to stabilize mood and control agitation. They are regarded for their effectiveness, but their side effects may limit their usage in some patient categories. On the other hand, second-generation antipsychotics have gained popularity due to their reduced risk of side effects compared to their predecessors, making them a preferred choice for clinicians dealing with delirium in vulnerable patient populations. These medications play a significant role in managing psychotic symptoms and are particularly relevant in treating older adults, who are at a higher risk for complications from delirium. Benzodiazepines are another important category in the Drug segment, used for their calming effects and ability to manage anxiety or agitation in patients experiencing delirium. However, their use must be balanced with the potential for adverse effects, including dependency and cognitive impairment. The US Delirium Market dynamics reflect these segments' apparent need, with a shift towards treatments that improve patient outcomes while minimizing risks. Furthermore, ongoing advancements in pharmacotherapy are likely to enhance the efficacy of these medications, providing healthcare professionals with more tools to manage delirium effectively. The growth drivers in this market are driven by increasing awareness among healthcare providers about delirium's implications and the rise in research focusing on optimal management strategies. As trends favor personalized medicine, the development and use of these drugs are expected to evolve, offering new hope for patients suffering from delirium and improving the overall quality of care in the US healthcare system. With an emphasis on patient safety and quality of life, the Drug segment remains a pivotal area of focus in the US Delirium Market industry. The integration of better diagnostic and treatment options will likely support market growth, resulting in positive US Delirium Market Statistics in the years to come as healthcare professionals strive for optimal solutions to manage this complex clinical condition. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Delirium Market Distribution Channel Insights** The Distribution Channel segment of the US Delirium Market has shown significant evolution, highlighting various pathways through which delirium management products are made available to patients. Retail Pharmacies play a critical role as they serve as the primary access point for many consumers, often providing immediate medication needs and facilitating patient consultations. Hospital Pharmacies are vital as well, given their involvement in the direct treatment environment and the ready availability of specialized medications tailored for inpatient care. Furthermore, Online Pharmacies have rapidly gained traction, reflecting the growing trend toward digital solutions and convenience in healthcare accessibility, particularly in a post-pandemic world. The integration of technology in the pharmacy sector has transformed patient purchasing habits, and online platforms now represent a significant share of the market due to their convenience and wide reach. The US Delirium Market segmentation shows that each distribution channel has its unique strengths, shaping the continuum of care for delirium patients and ultimately influencing market growth and dynamics. The rising prevalence of delirium, combined with an increase in awareness and the need for timely treatment options, fosters an environment for these channels to expand their roles in managing this complex condition. ### **Delirium Market Type Insights** The US Delirium Market, specifically categorized by type, includes Hyperactive, Hypoactive, and Mixed forms of delirium. Each type presents distinct characteristics and clinical manifestations, significantly impacting diagnosis and treatment strategies. Hyperactive delirium often involves heightened psychomotor activity, agitation, and aggressive behavior, which poses challenges in clinical settings like hospitals. In contrast, Hypoactive delirium is marked by lethargy and reduced activity levels, making it frequently underdiagnosed. The Mixed type combines features of both hyperactive and hypoactive delirium, complicating management approaches further. Recognizing the differences among these types is crucial for appropriate treatment interventions and can influence patient outcomes. The growing prevalence of delirium cases in the US, particularly among the elderly, highlights the importance of these classifications, as they guide healthcare providers in making informed decisions based on patient presentation. With ongoing advancements in clinical practices and a focus on tailored interventions based on type, the US Delirium Market continues to evolve, necessitating comprehensive understanding and strategies for effective management. ### **Delirium Market Diagnosis Insights** The Diagnosis segment within the US Delirium Market plays a crucial role in effectively identifying and managing this complex condition, which affects a significant number of hospitalized patients, particularly the elderly. Laboratory tests, including blood and urine tests, are essential as they help in ruling out underlying medical issues that might contribute to delirium, such as infections or metabolic imbalances. Physical examination is a fundamental step in assessing cognitive function and overall health, enabling healthcare providers to observe behavioral changes indicative of delirium. Imaging tests are increasingly vital for diagnosing delirium-related complications and identifying intracranial issues, providing a clearer understanding of a patient’s condition. As awareness of delirium's impact on the healthcare system grows, advancements in these diagnostic methods continue to improve accuracy and speed, thereby facilitating timely interventions. These developments are essential not only for patient outcomes but also for reducing healthcare costs associated with prolonged hospital stays and complications. Overall, the Diagnosis segment is gaining importance in the US healthcare landscape, driven by an increasing focus on geriatric care and the overall rise in awareness regarding delirium management. ### **Delirium Market End-User Insights** The US Delirium Market is seeing dynamic growth across various End-User categories, including Hospitals, Research Centers, and Specialty Centers. Hospitals play a crucial role in the management and treatment of delirium, equipped with specialized staff and resources to provide immediate care to patients at risk. Research Centers contribute significantly to advancing understanding and treatment methods for delirium, facilitating clinical trials and breakthrough studies that enhance patient outcomes. Specialty Centers, focusing on specific patient populations, offer targeted therapies and tailored rehabilitation, addressing unique challenges associated with delirium. The segmentation is vital as it reflects distinct care pathways and treatment methodologies that impact patient recovery. The growing emphasis on improving healthcare quality and outcomes, driven by aging populations and chronic illness prevalence in the US, further enhances the significance of these End-Users. Additionally, the need for innovative research and specialized care presents numerous opportunities for stakeholders, supporting the overall development of the US Delirium Market and ensuring comprehensive patient care. ## **US Delirium Market Key Players and Competitive Insights** The US Delirium Market is characterized by a complex landscape involving various pharmaceutical companies, each striving to gain a competitive edge through innovative drug development and strategic collaborations. Factors such as increasing awareness of delirium, advancements in treatment protocols, and the growing aging population are driving the demand for effective therapeutic solutions. Companies compete not only on the efficacy of their products but also on their ability to navigate regulatory challenges and provide comprehensive patient support services. The competitive dynamics necessitate continuous investment in research and development and a keen understanding of market needs for better positioning. Bristol Myers Squibb holds a notable position in the US Delirium Market, driven by its strong reputation for high-quality pharmaceuticals and effective treatments. The company benefits from a robust portfolio that includes drugs that have shown efficacy in managing delirium-associated conditions. Its commitment to research and development has enabled the company to invest in innovative therapies that are crucial in addressing the unmet needs of patients. Bristol Myers Squibb also emphasizes collaboration with healthcare providers to enhance treatment outcomes, reflecting its focus on patient-centered services. The company’s established relationships with healthcare institutions further enhance its market presence, as it leverages its strengths to maintain a competitive advantage. AstraZeneca is another significant player in the US Delirium Market, known for its comprehensive range of therapeutic products targeting various conditions related to delirium. The company’s strong presence in the US is bolstered by its innovative pipeline and strategic mergers and acquisitions that have expanded its capabilities and market reach. AstraZeneca emphasizes its commitment to research, focusing on developing novel medications that can improve patient care in delirium management. The company is recognized for its strengths in establishing partnerships with healthcare professionals, which aids in the effective dissemination of its key products. With a well-respected reputation and an expanding product portfolio, AstraZeneca continues to solidify its place in the market, adapting to the evolving needs of patients and healthcare providers in the US. ### **Key Companies in the US Delirium Market Include** ## **US Delirium Market Industry Developments** Recent developments in the US Delirium Market indicate a growing focus on innovative treatment approaches. Bristol Myers Squibb is advancing its research initiatives, aiming to improve therapeutic outcomes. AstraZeneca and Eli Lilly have also made strides, enhancing their medication portfolios to better address delirium symptoms. In terms of market activity, notable mergers and acquisitions include Merck's acquisition of a small biotech firm in August 2023 to bolster its delirium treatment pipeline, recognized by multiple industry outlets. Additionally, Novartis reported a successful clinical trial for a new drug aimed at preventing delirium in post-operative patients, showcasing their commitment to addressing this condition. Pfizer and H Lundbeck are exploring collaboration opportunities to develop cognitive-enhancing agents for delirium management, reflecting an ongoing trend of partnerships in this space. The US Delirium Market is witnessing marked growth, partly driven by an increasing awareness of delirium's impact on patient outcomes across healthcare settings. Over the past few years, significant research funding has been allocated, highlighting the urgency and importance of developing effective treatments. This evolving market landscape is indicative of an understanding of the complexities surrounding delirium and its broader implications in clinical contexts. ## **Delirium Market Segmentation Insights** ### **Delirium Market Drug Outlook** ### **Delirium Market Distribution Channel Outlook** ### **Delirium Market Type Outlook** ### **Delirium Market Diagnosis Outlook** ### **Delirium Market End-User Outlook** ## Market Drivers ### Increased Research Funding The surge in research funding dedicated to understanding and treating delirium is a significant driver for the delirium Market. Government and private institutions are allocating substantial resources to investigate the underlying mechanisms of delirium and its long-term effects. For instance, the National Institutes of Health (NIH) has increased its funding for delirium-related research, which has seen a rise of over 20% in recent years. This influx of financial support is likely to foster innovation in treatment modalities and diagnostic tools, thereby enhancing the overall market landscape. As new findings emerge, they may lead to the development of targeted therapies, further propelling the growth of the delirium Market. ### Rising Incidence of Delirium The increasing incidence of delirium among hospitalized patients is a critical driver for the delirium Market. Studies indicate that approximately 30% of hospitalized patients experience delirium, particularly among the elderly population. This rise in cases necessitates enhanced diagnostic tools and treatment options, thereby expanding the market. The aging population in the US, projected to reach 73 million by 2030, further exacerbates this issue. As healthcare providers become more aware of the prevalence and impact of delirium, there is a growing demand for effective management strategies. Consequently, this trend is likely to stimulate growth in the delirium Market, as stakeholders seek innovative solutions to address the needs of this vulnerable patient demographic. ### Integration of Digital Health Solutions The integration of digital health solutions into delirium management represents a transformative driver for the delirium Market. Telehealth platforms and mobile applications are increasingly being utilized to monitor patients at risk of delirium, providing real-time data to healthcare providers. This trend is particularly relevant in the context of an aging population, where remote monitoring can enhance patient care and reduce hospital readmissions. The digital health market is projected to grow significantly, with estimates suggesting a compound annual growth rate (CAGR) of over 25% in the coming years. As these technologies become more prevalent, they are likely to reshape the landscape of the delirium Market, offering innovative ways to manage and prevent delirium. ### Regulatory Support for Delirium Management Regulatory bodies in the US are increasingly emphasizing the importance of delirium management, which acts as a catalyst for the delirium Market. Initiatives aimed at improving patient safety and quality of care have led to the establishment of guidelines that encourage the identification and treatment of delirium. For example, the Centers for Medicare & Medicaid Services (CMS) has introduced measures that incentivize hospitals to implement delirium screening protocols. This regulatory support is likely to drive the adoption of new technologies and treatment options, as healthcare providers seek to comply with these standards. Consequently, the delirium Market may experience accelerated growth as stakeholders respond to these regulatory changes. ### Growing Demand for Non-Pharmacological Interventions There is a notable shift towards non-pharmacological interventions in the management of delirium, which serves as a key driver for the delirium Market. Healthcare providers are increasingly recognizing the importance of holistic approaches, such as cognitive stimulation and environmental modifications, in preventing and managing delirium. This trend is supported by evidence suggesting that non-pharmacological strategies can reduce the incidence of delirium by up to 50%. As hospitals and care facilities adopt these practices, the demand for related products and services is expected to rise. This shift not only enhances patient outcomes but also creates new opportunities within the delirium Market for innovative solutions that align with these evolving care paradigms. ## Future Outlook The [Delirium Market](https://www.marketresearchfuture.com/reports/delirium-market-5850) is projected to grow at a 5.3% CAGR from 2025 to 2035, driven by increasing awareness, technological advancements, and enhanced healthcare services. **New opportunities:** - Development of AI-driven diagnostic tools for early detection. - Expansion of telehealth services for remote patient monitoring. - Investment in training programs for healthcare professionals on delirium management. By 2035, the market is expected to achieve substantial growth, reflecting evolving healthcare needs. ## Segment Insights ### By Type: Hyperactive (Largest) vs. Mixed (Fastest-Growing) In the US delirium market, the distribution of segment values reveals that the Hyperactive type holds the largest share, driven by its more noticeable symptoms that facilitate quicker diagnosis and treatment options. Conversely, the Mixed type is gaining traction, appealing to healthcare professionals due to its complex nature and diverse symptoms that might require multifaceted treatment approaches. Each type plays a significant role in the overall market dynamics, influencing healthcare strategies and resource allocation. Growth trends within the US delirium market indicate a rising awareness and diagnosis of delirium types, which fuels the demand for tailored treatment plans. The increased investment in research and development for better management of Mixed type delirium is contributing to its rapid growth. Healthcare providers are focusing on comprehensive solutions that encompass all types, ensuring that they can address varying patient needs effectively. This trend reflects a broader shift towards personalized medicine, driven by the need for improved patient outcomes. Hyperactive (Dominant) vs. Mixed (Emerging) The Hyperactive type of delirium is characterized by heightened alertness, agitation, and restlessness, making it easily identifiable and often prioritized in treatment protocols. Its prominence in the US delirium market stems from the urgency it demands for intervention, thereby securing a dominant position. In contrast, the Mixed type presents a more complex clinical picture, encompassing features of both hyperactive and hypoactive states. As an emerging segment, it requires innovative approaches to address its diverse presentations. The Mixed type is gaining attention for its potential to affect wider patient demographics, thereby fostering increased research efforts and growing healthcare interest, marking a significant shift in how delirium is approached. ### By Diagnosis and Treatment: Diagnosis (Largest) vs. Treatment (Fastest-Growing) In the US delirium market, the diagnosis segment holds a significant market share, driven by the rising awareness and technological advancements in diagnostic tools. The emphasis on accurate and timely diagnosis is paramount, leading to a stable demand for diagnostic services. Conversely, the treatment segment is witnessing rapid growth due to increasing investments in research and development of new therapeutic options, making it a pivotal area in delirium management. The growth trends in this segment are primarily fueled by an aging population and rising incidences of delirium, amplifying the need for effective diagnosis and treatment strategies. Innovations, such as digital health solutions and personalized medicine, are further propelling this market. These trends reflect a shift towards more integrated and efficient care models, enhancing the overall outlook for both diagnosis and treatment segments. Diagnosis (Dominant) vs. Treatment (Emerging) The diagnosis segment is currently dominant in the US delirium market, characterized by advanced imaging techniques and the use of biomarkers to enhance diagnostic accuracy. This segment benefits from established protocols and a robust infrastructure for clinical assessments. In contrast, the treatment segment, while emerging, is gaining traction with advancements in pharmacotherapy and non-pharmacological approaches. As research continues to evolve, treatment options are becoming more diverse, catering to the unique needs of patients. Overall, both segments complement each other, as accurate diagnosis is essential for effective treatment. ### By End User: Hospitals (Largest) vs. Research Centers (Fastest-Growing) The market share distribution in the US delirium market market clearly shows that hospitals hold the largest share, underscoring their critical role in patient care. This segment is foundational, given that hospitals are primary treatment centers for acute delirium cases, thus driving a significant portion of the market's revenue. In contrast, specialty care facilities and research centers, while smaller in share, are growing rapidly, reflecting emerging trends in targeted delirium management and innovative treatment research. Growth trends in the US delirium market market are heavily influenced by the rising prevalence of delirium, particularly among older populations. Furthermore, advancements in medical technologies and increased awareness of delirium’s impact on recovery outcomes are propelling the demand for specialized care in hospitals and research centers. Investment in research is proving essential, enabling the development of new interventions, which suggests sustained growth in these segments over the coming years. Hospitals (Dominant) vs. Research Centers (Emerging) In the US delirium market market, hospitals are the dominant force due to their capacity to handle acute cases, infrastructure, and personnel trained in managing delirium and its complications. This segment benefits from established protocols and funding, allowing for better patient outcomes and greater efficiency in treatment. On the other hand, research centers are recognized as emerging players. They are vital for fostering innovation and translating research into clinical practices that address delirium, and their role is expanding as the need for specialized delirium protocols increases. The synergy between these segments ensures comprehensive care and the potential for groundbreaking advancements in delirium management. ## Competitive Benchmarking The delirium market exhibits a complex competitive landscape characterized by a blend of innovation, strategic partnerships, and a focus on patient-centric solutions. Key players such as Johnson & Johnson (US), Pfizer Inc. (US), and Eli Lilly and Company (US) are actively shaping the market dynamics through their distinct operational strategies. Johnson & Johnson (US) emphasizes innovation in drug development, particularly in neuropsychiatric treatments, while Pfizer Inc. (US) focuses on expanding its portfolio through strategic acquisitions and collaborations aimed at enhancing therapeutic options for delirium. Eli Lilly and Company (US) is also notable for its commitment to research and development, particularly in the realm of cognitive disorders, which positions it favorably in the competitive environment.The business tactics employed by these companies reflect a concerted effort to optimize supply chains and localize manufacturing processes. The market structure appears moderately fragmented, with several players vying for market share, yet the influence of major companies remains substantial. This competitive structure allows for a diverse range of treatment options, catering to the varying needs of healthcare providers and patients alike. In October Johnson & Johnson (US) announced a partnership with a leading technology firm to integrate AI-driven analytics into its clinical trials for delirium treatments. This strategic move is likely to enhance the efficiency of drug development processes and improve patient outcomes by enabling more personalized treatment approaches. The integration of AI signifies a shift towards data-driven decision-making in the pharmaceutical sector, which could set a new standard for clinical research. In September Pfizer Inc. (US) launched a new initiative aimed at increasing access to delirium treatments in underserved communities. This initiative, which includes partnerships with local healthcare providers, underscores Pfizer's commitment to addressing health disparities and expanding its market reach. By focusing on accessibility, Pfizer not only enhances its corporate social responsibility profile but also positions itself as a leader in equitable healthcare solutions. In August Eli Lilly and Company (US) unveiled a groundbreaking study demonstrating the efficacy of its latest drug candidate for delirium management. This announcement is pivotal as it not only reinforces Eli Lilly's reputation for innovation but also potentially opens new avenues for treatment protocols in clinical settings. The positive results from this study may lead to increased market penetration and bolster Eli Lilly's competitive standing. As of November the competitive trends in the delirium market are increasingly defined by digitalization, sustainability, and the integration of advanced technologies such as AI. Strategic alliances are becoming more prevalent, facilitating knowledge sharing and resource optimization among key players. Looking ahead, the competitive differentiation is likely to evolve from traditional price-based strategies to a focus on innovation, technological advancements, and the reliability of supply chains. This shift indicates a broader transformation in the market, where companies that prioritize research and development, alongside sustainable practices, may emerge as frontrunners. ## Recent News & Developments Recent developments in the US Delirium Market indicate a growing focus on innovative treatment approaches. Bristol Myers Squibb is advancing its research initiatives, aiming to improve therapeutic outcomes. AstraZeneca and Eli Lilly have also made strides, enhancing their medication portfolios to better address delirium symptoms. In terms of market activity, notable mergers and acquisitions include Merck's acquisition of a small biotech firm in August 2023 to bolster its delirium treatment pipeline, recognized by multiple industry outlets. Additionally, Novartis reported a successful clinical trial for a new drug aimed at preventing delirium in post-operative patients, showcasing their commitment to addressing this condition. Pfizer and H Lundbeck are exploring collaboration opportunities to develop cognitive-enhancing agents for delirium management, reflecting an ongoing trend of partnerships in this space. The US Delirium Market is witnessing marked growth, partly driven by an increasing awareness of delirium's impact on patient outcomes across healthcare settings. Over the past few years, significant research funding has been allocated, highlighting the urgency and importance of developing effective treatments. This evolving market landscape is indicative of an understanding of the complexities surrounding delirium and its broader implications in clinical contexts. ## Report Scope | MARKET SIZE 2024 | 70.98(USD Million) | | --- | --- | | MARKET SIZE 2025 | 74.74(USD Million) | | MARKET SIZE 2035 | 125.3(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 5.3% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Johnson & Johnson (US), Roche Holding AG (CH), Pfizer Inc. (US), Bristol-Myers Squibb Company (US), Eli Lilly and Company (US), Novartis AG (CH), AstraZeneca PLC (GB), Merck & Co., Inc. (US), Sanofi S.A. (FR) | | Segments Covered | Type, Diagnosis and Treatment, End User | | Key Market Opportunities | Advancements in digital therapeutics enhance patient monitoring and treatment options in the delirium market market. | | Key Market Dynamics | Rising awareness of delirium management drives innovation and competition among healthcare providers and pharmaceutical companies. | | Countries Covered | US | ## Frequently Asked Questions **Q: What was the overall market valuation of the US delirium market in 2024?** A: The overall market valuation was $70.98 Million in 2024. **Q: What is the projected market valuation for the US delirium market by 2035?** A: The projected valuation for 2035 is $125.3 Million. **Q: What is the expected CAGR for the US delirium market during the forecast period 2025 - 2035?** A: The expected CAGR for the US delirium market during the forecast period 2025 - 2035 is 5.3%. **Q: Which companies are considered key players in the US delirium market?** A: Key players in the market include Johnson & Johnson, Roche Holding AG, Pfizer Inc., and others. **Q: What are the market segments for the US delirium market?** A: The market segments include Type, Diagnosis and Treatment, and End User. **Q: What was the valuation for the Hyperactive type segment in 2024?** A: The valuation for the Hyperactive type segment was between $20.0 Million and $35.0 Million in 2024. **Q: What is the projected valuation for the Treatment segment by 2035?** A: The projected valuation for the Treatment segment is between $40.59 Million and $71.18 Million by 2035. **Q: How does the valuation for Hospitals compare to Research Centers in 2024?** A: In 2024, the valuation for Hospitals was between $30.39 Million and $53.12 Million, whereas Research Centers ranged from $14.9 Million to $27.06 Million. **Q: What is the expected growth trend for the Hypoactive type segment from 2024 to 2035?** A: The Hypoactive type segment is expected to grow from a valuation of $25.0 Million to $45.0 Million by 2035. **Q: What does the market data suggest about the future of the US delirium market?** A: The market data suggests a robust growth trajectory, with a projected increase in valuation and a steady CAGR of 5.3% during 2025 - 2035. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-delirium-market-19916*